Running title: CK2 inhibitor enhances vitamin D mediated anti-tumor effects
Introduction
The most physiologically active form of the prohormone, vitamin D 3 (cholecalciferol), is 1,25-dihydroxyvitamin D 3 (1,25D 3 ). 1,25D 3 plays a key role in the regulation of calcium homeostasis and bone metabolism through effects on tissues such as bone, gut and kidney (1, 2) . Non-classical roles for 1,25D 3 including the regulation of proliferation, differentiation and immune function have now been identified in a variety of cell types (3) . The serum level of 1,25D 3 is highly regulated through synthesis facilitated by 1-alpha-hydroxylase (CYP27B1), and through inactivation by 24-hydroxylase (CYP24A1) (1, 2) .
CYP24A1 is transcriptionally regulated by the interaction between the vitamin D receptor (VDR)-retinoid-X-receptor (RXR) heterodimer and vitamin D response elements
(VDREs) on CYP24A1 gene (4) (5) (6) . In the absence of 1,25D 3 , VDR/RXR hetero-dimers bind to these VDREs and repress transcription through interactions with a co-repressor complex that has histone de-acetylase activity (7) . In the presence of 1,25D 3 , the corepressor complex is released, permitting the recruitment of a co-activator complex that leads to the activation of the gene (8, 9) . 1,25D 3 also stimulates rapid non-genomic effects in some cell-types via the ERK1/ERK2/ERK5, PKC, or JNK MAP kinase modules through a cell-membrane-associated VDR (3).
The prostate cancer cell lines DU145 and PC3were purchased from American Type Culture Collection (ATCC) and used within 6 months after resuscitation. Cell lines were authenticated by ATCC with short tandem repeat (STR) DNA profiling and cytogenetic analysis. Cells were maintained in culture according to providers' protocols for a maximum of 10 passages (one month).
Generation of stable reporter cell line
pGL4.21 vector expressing the firefly luciferase gene under the control of CYP24A1 promoter was constructed by the insertion of CYP24A1 promoter using NheI and XhoI restriction enzyme sites (23) . A stable human prostate cancer PC3 cell line expressing CYP24A1 promoter-driving luciferase reporter (PC3/CYP24A1) was generated by transfection using lipofectamine 2000 followed by puromycin selection. 
Chemical library and high throughput screening

Quantitative reverse transcriptase PCR (qRT-PCR)
Expression of CK2, CYP24A1, TRPV6, p21 Waf1 and GADD45A mRNA was assessed by qRT-PCR using TaqMan® Gene Expression Assay and normalized to the human GAPDH and samples were analyzed in triplicate.
Immunoblotting analysis
Whole cell lysates were prepared and Western blot analysis performed as described previously (24) . 
Immunohistochemistry
Tissue staining with anti-Ki-67 and anti-cleaved Caspase-3 was conducted as described previously (22) .
TUNEL assay
Nuclear DNA fragmentation in situ was detected using TACS-XL In Situ Apoptosis
Detection Kit according to the manufacture's instruction (R&D system, Minneapolis, MN). 
Statistics
Results
Screening of small molecules from LOPAC
1280 Library by CYP24A1 promoter driving reporter assay A stable human prostate cancer PC3 cell line expressing CYP24A1 promoter-driving luciferase reporter was generated by transfection using lipofectamine 2000 followed by puromycin selection. Screening of the LOPAC 1280 library in this system resulted in the identification of 70 hits each of which had over 50% inhibition of 1,25D 3 -induced CYP24A1 promoter activity. (Fig. 1A ) Excluding the hits with high toxicity, known from Small Molecule Screening Core (SMSC) database, twenty-one selected molecules were subjected to secondary dose-response experiments to confirm initial observations.
Seventeen hits reduced 1,25D 3 -mediated CYP24A1 promoter activation (Fig. 1B) . Among them, 4,5,6,7-tetrabromobenzimidazole (TBBz) displayed the strongest inhibitory effect and was chosen for further investigation ( Fig. 1A and 1B).
Repression of CYP24A1 transcriptional activity by TBBz
To confirm the results from the screening, we examined the effect of various concentration of TBBz on CYP24A1 promoter activity in PC3/CYP24A1 cells. Results
showed that TBBz inhibited CYP24A1 promoter activity in a dose dependent manner ( 
Reduction of CYP24A1 expression by siRNA-CK2
TBBz is a selective protein kinase CK2 inhibitor (26) . To investigate whether CK2 plays a role in the regulation of CYP24A1 expression, siRNA-CK2 was transfected in prostate cancer PC3 or DU145 cells for 72 hours followed by the addition of 1,25D 3 . CYP24A1 mRNA and CYP24A1 protein were measured by qRT-PCR and Western blot, respectively. Results showed that PC3 and DU145 cells express CK2 and CK2 was effectively knocked down by siRNA-CK2 in PC3 and DU145 cells compared to control siRNA ( Fig. 2A and 2B ). 1,25D 3 significantly (P < 0.01) increased CYP24A1 expression in PC3 cells, which express a low level of endogenous CYP24A1 ( Fig. 2A and 2C, respectively), and in DU145 cells, which display a high level of endogenous CYP24A1 (Fig. 2B and 2D , respectively). Transfection with siRNA-CK2 significantly reduced 1,25D 3 -induced CYP24A1 expression at both mRNA and protein level in PC3 ( Fig. 2A and 2C) and DU145 cells (Fig. 2B and 2D ) as compared with the mock-transfected or siRNA control transfected samples. These results indicate that CK2 plays a role in regulation of 1,25D 3 -induced CYP24A1 expression. 3A ). In contrast, knockdown of CK2 markedly increased p21 Waf1 and slightly increased GADD45A mRNA expression ( Fig. 3B and 3C ). These results indicate that silencing of CK2 differentially affects the expression of vitamin D target genes.
Correlation of increased CYP24A1 expression with increased CK2 expression in human prostate tumors
We analyzed mRNA expression of CYP24A1 and CK2 in 30 matched pair of human normal and tumor prostate samples by qRT-PCR. CK2 expression was significantly increased in prostate tumor lesions compared to normal lesions (P = 0.0224) (Fig. 4) .
There was no correlation of the level of CYP24A1 expression and CK2 expression with 
Enhancement of 1,25D 3 anti-proliferative activity by TBBz or siRNA-CK2
To ascertain the potential therapeutic role of CK2 inhibitors in 1,25D 3 anti-tumor action, cell viability and cell proliferation was examined using the trypan blue exclusion assay after treatment with 1,25D 3 , TBBz, or the combination of 1,25D 3 and TBBz for 9 days.
Combination treatment of 1,25D 3 and TBBz resulted in a significant (P < 0.05) enhancement of 1,25D 3 anti-proliferative effect in PC3 cells (Fig. 5A) . We also measured CYP24A1 mRNA expression on day 1 and day 9. We observed that CYP24A1 mRNA expression kept lower in PC3 cells treated with the combination of 1,25D 3 and TBBz which showed the most antiproliferative activity compared to cells treated with 1,25D 3 alone (Supplementary Fig. 1B) . Instead of 1,25D 3 , 25D 3 in combination of TBBz also caused a greater inhibition of proliferation in PC3 cells than when treated with either agent alone (Supplementary Fig. 2B ).
To more specifically investigate the importance of CK2 in 1,25D 3 anti-proliferative effect, siRNA-CK2 was employed. siRNA-CK2 significantly (P < 0. 
anti-proliferative effect in PC3 cells (Fig. 5B) . This indicates that CK2 inhibition is antiproliferative and enhances 1,25D 3 anti-proliferative effect.
Enhancement of 1,25D 3 anti-tumor activity by TBBz in vivo
Having demonstrated the efficacy of the combination treatment of 1,25D 3 and TBBz in vitro, we next assessed both toxicity and efficacy of the combination treatment in a PC3
prostate tumor xenograft mouse model. We observed a marked inhibition of tumor growth by the combination of 1,25D 3 and TBBz, compared to 1,25D 3 or TBBz alone (Fig.   6A ). Mice grew normally without suffering from weight loss at a dose sufficient to induce anti-tumor effect (Fig. 6B) . These results indicate that CK2 inhibitor TBBz enhances 1,25D 3 anti-tumor activity in vivo.
Effect of the combination of 1,25D 3 and TBBz on tumor cell CYP24A1 expression, proliferation and apoptosis in in vivo
To investigate the effect of TBBz on CYP24A1 expression in vivo, tumor tissues were harvested at the end of the treatment described in Fig. 5A , and CYP24A1 mRNA expression was measured by qRT-PCR. 1,25D 3 increased CYP24A1 expression and TBBz reduced CYP24A1 expression in tumors as compared to saline group (Fig. 6C) . To further elucidate the molecular mechanisms for the anti-tumor activity of 1,25D 3 and TBBz in vivo, we examined the proliferation marker Ki-67 and apoptosis marker cleaved caspase-3 as well as in situ DNA fragmentation (TUNEL) in tumor tissues (Fig. 6D) . The results showed that saline-treated tumor tissue had strong Ki-67 staining, 1,25D 3 or TBBz reduced Ki-67 staining (Fig. 6D) . The combination of 1,25D 3 and TBBz further reduced Ki-67 staining (Fig. 6D) . We also observed that saline group did not have positive cleaved caspase-3 staining, whereas 1,25D 3 or TBBz treatment alone induced caspase-3 cleavage in the tumor tissue (Fig. 6D ). The combination of 1,25D 3 and TBBz further enhanced caspase-3 cleavage (Fig. 6D ). The effect of 1,25D 3 and TBBz on apoptosis was further confirmed by TUNEL assay (Fig. 6D) 
Discussion
The majority of CYP24A1 inhibitors developed so far target the enzyme activity.
However, decreased enzyme activity with current CYP24A1 inhibitors is often associated with increased enzyme expression which negatively impacts on the vitamin D-mediated anti-tumor activity (19, 21, 27) . In this study, the strategy we utilized to identify new CYP24A1 inhibitors differs from previously described (28) . We established a stable PC3 cell line, which express luciferase driven by CYP24A1 promoter, to screen a small molecular library containing 1280 compounds. We identified 17 new CYP24A1 inhibitors, TBBz being the strongest was selected for further characterization, which Protein kinase CK2 is an evolutionarily conserved serine/threonine kinase which is ubiquitously expressed in human tissues. CK2 is located both in cytosol and nucleus (29, 30) . Overexpression of CK2 has been noted in a variety of human cancers including prostate cancer and correlates with a poor clinical outcome (31) (32) (33) (34) . Inhibition of CK2 activity reduced cell proliferation in prostate cancer cells (35, 36) . The role for CK2 in the regulation of CYP24A1 gene expression in tumor has not been described before. Our study shows that CK2 positively regulates CYP24A1 expression. We further show that CK2 expression was higher in tumor lesions compared to normal lesions (P = 0.0224) (Fig. 4) . Increase of CK2 expression was significantly (P=0.0331) associated with increased CYP24A1 expression in these prostate tumor samples. These observations suggest that CK2 may serve as a mechanism for controlling CYP24A1 expression in human cancers, and therefore supporting the use of CK2 inhibitors for cancer treatment in combination with 1,25D 3 .
CYP24A1 expression is heterogeneous in prostate cancer (23) . It is noteworthy that three human prostate tumor samples with high CK2 expression did not express high level of CYP24A1 and three prostate tumor samples with high CYP24A1 expression did not express high level of CK2 compared to normal lesions (table 1). These data suggest that the level of CK2 expression does not entirely account for the level of CYP24A1 expression in human prostate tumor. Previous studies indicated multiple events are associated with CYP24A1 expression in cancer, such as methylation and histone modification associated with the CYP24A1 promoter (3, 23, 37) , amplification at the CYP24A1 locus (13) and miRNA regulation (38) .
We also observed that the silencing of CK2 differentially affects vitamin D target genes.
We observed the significant reduction of 1,25D 3 -induced TRPV6 in siRNA-CK2 transfected PC3 cells. Up-regulation of TRPV6 by 1,25D 3 in prostate cancer cells is considered to be pro-proliferative by increasing Ca 2+ -uptake (39, 40 (19, (41) (42) (43) . GADD45A is identified as a primary target gene for 1,25D 3 in ovarian, testicular and prostate cancer cells (19, 44, 45) . The increase in GADD45A expression leads to a decrease of cyclin B and induces G2/M cell cycle arrest (45, 46) . In the present study, the reduction of CYP24A1 and TRPV6 expression and the increase in the p21 waf1 and GADD45A expression by the combination of 1,25D 3 and siRNA-CK2 may be reflective of the co-operative growth inhibition observed from the cell-proliferation assay.
However, the exact mechanisms underlying the effect of CK2 on 1,25D 3 -mediated In summary, we developed a new strategy to identify novel CYP24A1 inhibitors. 
